Sonosensitive MRI nanosystems as cancer theranostics: A recent update by Garello, Francesca & Terreno, Enzo
MINI REVIEW
published: 07 May 2018
doi: 10.3389/fchem.2018.00157
Frontiers in Chemistry | www.frontiersin.org 1 May 2018 | Volume 6 | Article 157
Edited by:
Zsolt Baranyai,
Bracco Imaging S.p.A., Italy
Reviewed by:
Ahmed El-Fiqi,
Dankook University, South Korea
István Bányai,
University of Debrecen, Hungary
*Correspondence:
Enzo Terreno
enzo.terreno@unito.it
Specialty section:
This article was submitted to
Medicinal and Pharmaceutical
Chemistry,
a section of the journal
Frontiers in Chemistry
Received: 05 February 2018
Accepted: 19 April 2018
Published: 07 May 2018
Citation:
Garello F and Terreno E (2018)
Sonosensitive MRI Nanosystems as
Cancer Theranostics: A Recent
Update. Front. Chem. 6:157.
doi: 10.3389/fchem.2018.00157
Sonosensitive MRI Nanosystems as
Cancer Theranostics: A Recent
Update
Francesca Garello and Enzo Terreno*
Molecular and Preclinical Imaging Centers, Department of Molecular Biotechnology and Health Sciences, University of
Torino, Torino, Italy
In the tireless search for innovative and more efficient cancer therapies, sonosensitive
Magnetic Resonance Imaging (MRI) agents play an important role. Basically, these
systems consist of nano/microvesicles composed by a biocompatible membrane,
responsive to ultrasound-induced thermal or mechanical effects, and an aqueous core,
filled up with a MRI detectable probe and a therapeutic agent. They offer the possibility
to trigger and monitor in real time drug release in a spatio-temporal domain, with
the expectation to predict the therapeutic outcome. In this review, the key items to
design sonosensitive MRI agents will be examined and an overview on the different
approaches available so far will be given. Due to the extremely wide range of adopted
ultrasound settings and formulations conceived, it is hard to compare the numerous
preclinical studies reported. However, in general, a significantly better therapeutic
outcome was noticed when exploiting ultrasound triggered drug release in comparison to
traditional therapies, thus paving the way to the possible clinical translation of optimized
sonosensitive MRI agents.
Keywords: sonosensitive agents, image-guided drug release, ultrasounds, magnetic resonance imaging,
theranostics, thermosensitive liposomes, HIFU, LINFU
INTRODUCTION
New insights in cancer biology, along with the advances in early detection and treatment,
led to increased life expectancy, and reduced cancer related deaths. However, there is still a
strong need for more efficient, precise, and safer therapies. To decrease the systemic toxicity
of some chemotherapeutic agents, drug encapsulation into biocompatible nanovesicles, named
liposomes, has been envisaged. The FDA approval of Doxil R©/Caelyx R© in 1995, a doxorubicin
liposomal formulation, for the treatment of Kaposi sarcoma, metastatic breast cancer and recurrent
ovarian cancer (Barenholz, 2012), boosted the research for optimizing liposomal preparations.
Liposomes are highly versatile nanovesicles consisting of a phospholipid bilayer surrounding an
aqueous core; these vesicles can vary in size, shape, and lipid composition (Sessa and Weissmann,
1968). Basically, liposomes can carry drugs and/or other molecules, such as imaging or targeting
agents, both in their aqueous core and/or in the lipidic membrane.Liposomes are designed to
prevent drug extravasation into healthy tissues, prolong blood circulation time, improve drug
accumulation, and enhance bioavailability at the target site (Blanco et al., 2015). The accumulation
of liposomes into solid tumors is mostly due to peculiarities of the cancerous tissue, namely
increased blood supply, enhanced endothelial permeability and reduced lymphatic drainage,
resulting into the Enhanced Permeability and Retention (EPR) effect (Maeda et al., 2000).
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Once accumulated in the tumor, the drug needs to be released
from the carrier. For the nanomedicines currently approved
in clinics, this crucial step occurs spontaneously, i.e., following
the natural degradability of the nanocarrier interacting with
tissue components (Rizzitelli et al., 2015). However, to better
control this process, liposomes sensitive to endogenous (e.g.,
pH, redox potential, enzymatic activity) or exogenous (e.g., heat,
light, pressure) stimuli can be designed (Guo and Szoka, 2003).
Among different possibilities, in the last decade, considerable
attention has been devoted to the use of ultrasounds (US)
(Pong et al., 2006), as they are already clinically approved tools
for imaging and therapy. Moreover, they can be modulated in
terms of frequency and intensity according to the specific goal
to be achieved. In addition, in view of personalized medicine
based approaches, co-encapsulation of an imaging agent inside
the vesicle could be envisaged in order to follow the release
process and predict the therapeutic outcome. In this respect,
Magnetic Resonance Imaging (MRI), due to its outstanding
spatial resolution, low invasiveness and absence of limits in tissue
penetration could be regarded as the optimal imaging technique.
Small paramagnetic molecules can be loaded into liposomes
in order to spatio-temporally track drug delivery and/or drug
release. In the next paragraphs an overview on the different
sonosensitive MRI agents will be presented, with a focus on
ultrasound-based trigger mechanisms. Finally, some examples of
successful preclinical applications in this field will be reported.
ULTRASOUND TRIGGERED DRUG
RELEASE
Ultrasound is a form of mechanical energy characterized by
an acoustic pressure wave at frequencies beyond the upper
limit of the normal human sound range, which is from 20 to
20,000Hz. Basically, US are produced by a sound source vibrating
sinusoidally along time, back and forth in space (Xin et al.,
2016). In practice US are often produced by means of a ceramic
disk endowed with a piezoelectric effect and a specific radius.
The disk is inserted within a transducer linked to a waveform
function generator. The produced ultrasounds vary in frequency,
amplitude, intensity, and speed of propagation. Frequency is
the number of cycles of compressions and rarefactions in a
Abbreviations: CEST, Chemical Exchange Saturation Transfer; DOPE,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DPPE, 1,2-Dipalmitoyl-
sn-glycero-3-phosphoethanolamine; Gd-DOTP, Gadolinium-1,4,7,10-
tetraazacyclododecane-N,N’,N”,N”’-tetrakis(methylenephosphonic acid);
Gd-DTPA, Gadolinium-diethylenetriamine pentaacetic acid; Gd-DTPA-BMA,
Gadolinium-di-ethylenetriaininepentaacetic acid-bis(methylamide); Ln-
HPDO3A, Lanthanide-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane;
DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; DSPE-PEG2000,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (ammonium salt); DPPC, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; HIFU,
High Intensity Focused Ultrasound; MPPC, 1-palmitoyl-2-hydroxy-sn-glycero-
3-phosphocholine; MRI, Magnetic Resonance Imaging; NMR, Nuclear Magnetic
Resonance; pLINFU, Pulsed Low Intensity Non Focused Ultrasounds; PP, Packing
Parameter; PRFS, Proton Resonance Frequency Shift; SPIO, SuperParamagnetic
Iron Oxide; Tm, Transition Temperature; TSL, Thermosensitive Liposomes; US,
Ultrasounds; USPIO, Ultrasmall Iron Oxide Particles.
sound wave per second. Ultrasounds can be classified according
to frequency into low (20–200 kHz), medium (0.7–3.0 MHz),
or high (1–20 MHz) frequency waves. Low frequency US are
characterized by deeper tissue penetration. Moreover, US can be
further grouped according to intensity, defined as the quantity
of energy in the US beam area, into low intensity (<3 W/cm2)
or high intensity ultrasound (3–10,000 W/cm2) (ter Haar, 1999).
Low intensity ultrasounds are already clinically approved to
promote transdermal drug delivery, while high intensity US are
mainly used for thermal ablation of uterine fibroids, kidney
stone shattering, and palliative treatments. The possibility of
using pulsed or continuous waves, over a variable time range,
as well as focusing US by means of specific transducers, makes
this technique extremely versatile. Ultrasounds can induce drug
release in two different ways, namely by the mechanical or
thermal route.
US Mechanical Effect
The US mechanical effect is based upon a combination of
micromassage, cavitation and acoustic streaming. Micromassage
refers to US induced cell vibrations, likely affecting tissue fluid
interchange and tissue mobility. Cavitation is defined as the
phenomena of the formation, growth, and subsequent collapse
of microbubbles (Frenkel, 2008). Newly formed microbubbles
or administered sonosensitive vesicles can oscillate stably (stable
cavitation), inducing a constant fluid flow around the bubble,
called microstreaming, that induces stress on cell membranes,
and may enhance cell permeability. While, if the bubbles increase
more than twofold their size, they violently collapse (inertial
cavitation) causing microstreaming, formation of liquid jets and
ultrasound shock wave emission, able to disrupt membranes of
adjacent cells and create pores in capillary walls (Khokhlova
et al., 2015). As cavitation phenomena can induce severe
cytotoxic effects, a cavitation level sufficient to release drug
form nanovesicles and permeabilize cell membranes but without
killing cells should be induced (Pitt et al., 2004). To exploit
this wide range of mechanical effects, specific US responsive
nano-microsystem have been designed, mainly microbubbles
(Hernot and Klibanov, 2008), and liposomes (Schroeder et al.,
2007). More details about these systems are provided in section
Sonosensitive Systems.
US Thermal Effect
The thermal effect, recently reviewed by T. Boissenot et al.
(2016), is strictly linked to the application of high intensity US.
More in details by focusing the US beam in a small area of a
target tissue, the power per cross section area becomes extremely
high, leading to significant absorption of thermal energy from
the beam by the tissue and consequently resulting in local
temperature rise. Resulting hyperthermia could be mild (39–
42◦C) or high (>43◦C).Mild hyperthermia is generally employed
to trigger drug release, as it will be discussed in paragraph
Thermosensitive Systems. Whereas, high hyperthermia is mainly
exploited to kill or ablate tissues (Diederich and Hynynen,
1999): uterine fibroids, prostate, breast, pancreatic, and liver
cancers have been safely and successfully treated with High
Intensity Focused Ultrasound (HIFU). In this regard, precise,
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and constant temperature monitoring of the heated area is of
paramount importance; it can be obtained by means of invasive
thermocouples or by MRI thermometry.
ULTRASOUND RESPONSIVE AND MRI
DETECTABLE PROBES
So far, a number of reports has been published about the synthesis
and optimization of ultrasound responsive and MRI detectable
probes. The key components to design such systems are: (i)
a lipidic membrane stable in physiological conditions, able to
release its content selectively upon US exposure; (ii) a MRI
agent, encapsulated within the system, able to report on drug
release; (iii) an entrapped drug, that, upon release, carries out the
therapeutic effect (Figure 1).
Sonosensitive Systems
Initially invented as contrast agent for ultrasound imaging
and lately reconsidered for drug and gene delivery purposes,
microbubbles are micron sized systems made of an external
FIGURE 1 | Schematic illustration of the mechanism of a liposome-based
sonosensitive MRI agent. The MRI signal of a low water permeable liposome
entrapping a relatively high amount of a MRI agent is almost silent, due to the
compartmentalization of the probe. However, when the US stimulation triggers
the release of the agent, the MRI contrast activates, thus signaling the release
of the drug co-loaded in the nanocarrier.
shell encapsulating an inner gas core. These systems display a
strong tendency to undergo stable or inertial cavitation upon
US exposure. The shell could be made up of lipids, polymers
or proteins. The inner core could also be filled with liquid
perfluoropropane, then triggered to the gaseous phase when
stimulated with acoustic energy. Theranostic microbubbles were
prepared by Fan et al. bearing a phospholipidic shell, endowed
with a complex of SuperParamagnetic Iron Oxide (SPIO)
nanoparticles and doxorubicin, and filled with perfluoropropane
(Fan et al., 2016). Similar, nanosized, probes were developed by
Cavalli et al. (2015). Palmitic acid was the surfactant of choice
to be included in the shell in order to entrap the MRI agent Gd-
DOTP. Prednisolone phosphate (PLP) was added as therapeutic
agent, while pluronic F68 was used as stabilizing agent. Both
the preparations, however, were characterized by limited stability
over time (1–3 h).
To this regard, liposomes appear promising systems, but, in
order to be sonosensitive, special attention has to be dedicated
to their membrane composition. TJ Evjen (2011) highlighted the
important role played by the phospholipid Packing Parameter
(PP). Non-bilayer forming lipids with large hydrophobic cross
section as compared to the polar headgroup (PP >1), like
DOPE or DSPE, significantly promote liposome sonosensitivity
(Evjen et al., 2013). This effect is associated to a DOPE/DSPE
restructuring process: upon US exposure, a transformation
from lamellar to reversed hexagonal phase occurs, inducing the
formation of pores and/or tubular aggregates, through which
the drug can readily leak out (Kang et al., 2014). In order
to form liposomes, DOPE (or other phospholipids bearing PP
< 1) must be mixed with phospholipids displaying natural
tendency to form bilayers (PP∼1), cholesterol, useful to induce
mechanical stability by tightening the membrane, and stealth
moieties, to prolong blood circulation time. While the amount
of cholesterol, saturated phospholipids, and polymers should be
limited as they increase membrane stiffness and decrease the
tendency to drug leakage, stealth moieties, like DSPE-PEG2000
seems to enhance sonosensitivity by the so called “antenna
effect,” favoring the interactions between acoustic waves and the
vesicles. Finally, Giustetto et al. demonstrated that also shape,
size, and intravesicular composition of liposomes may influence
US triggered drug release (Giustetto et al., 2013).
Thermosensitive Systems
In 1978, Yatvin et al. first described a thermosensitive
formulation, consisting of a DPPC/DSPC (3:1) liposome able to
selectively release its hydrophilic content when the temperature
was raised up of a few degrees above physiological temperature
(Yatvin et al., 1978). Since then, many efforts have been made
to obtain improved formulations and to accurately monitor
temperature variations in the region of interest, where drug
release should take place. The fundamental points to be
fulfilled to design a good thermosensitive system are:(i) the
presence of temperature sensitive phospholipids or polymers
in the membrane; (ii) stable encapsulation of drugs at body
temperature; (iii) fast and complete drug release upon heat
stimulation and (iv) provision of high drug plasma levels
during the time span of hyperthermia treatment (Hijnen et al.,
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2014). The first thermosensitive liposomes (TSL) developed were
mainly composed of phosphatidylcholines, bearing a transition
temperature (Tm) in the range of mild hyperthermia (40–43
◦C).
Around Tm, the temperature at which a polymer/phospholipid
melts from the gel-ordered phase to the liquid-crystalline
phase, a significant drug release was achievable due to grain
boundaries between the two phases (Landon et al., 2011). In
1994 Unezaki et al. (1994) added 3% PEGylated phospholipids
to a DPPC/DSPC 9:1 formulation, resulting in prolonged
circulation time, due to PEG stealth effect, and better therapeutic
outcome. PEGylated phospholipids were then considered a basic
component.
A breakthrough occurred in 2000, when Needham and co-
workers proposed the inclusion of lysolipids (PP < 1) into
the membrane bilayer (DPPC/MPPC/DSPE-PEG2000 90:10:4),
obtaining 80% drug release around Tm in a few seconds, thanks to
the formation of lysolipids-stabilizedmembrane pores (Needham
et al., 2000). This innovation led to the birth of ThermoDox R©,
a TSL formulation containing lysolipids and doxorubicin, that
has reached phase III clinical trials for hepatocellular carcinoma
treatment (Bulbake et al., 2017). In recent years a myriad of subtle
variations has been made to the above-mentioned formulations
and different simulated or experimental models have been
developed to predict the complex interplay between liposome
properties, tumor perfusion, heating regimen, and therapeutic
efficacy (Gasselhuber et al., 2010, 2012; Lokerse et al., 2016, 2017).
Interestingly, Banno et al. drew the attention on the importance
of TSL formulation to retain liposome stability: they reported
that 70% of lysolipids was lost within 1 h post injection of TSL,
likely due to interactions with the large lipid membrane pool
in vivo, thus inducing non-triggered drug leakage (Banno et al.,
2010). The advantage of using HIFU as heating source is the
possibility to obtain a fast and localized temperature increase.
Moreover, spatial guidance and temperature monitoring are
nowadays available thanks to non-invasive MR-HIFU systems.
Among different magnetic resonance thermometry techniques
available, Proton Resonance Frequency Shift (PRFS) is by far the
most employed, with a precision of approximately 1◦C. Using the
MR-HIFU platform different focal points can be steered, heating
tissues of various volumes, meanwhile sparing vulnerable and
crucial structures (Hijnen et al., 2014). It has to bementioned that
MR-thermometry could be perturbed by MRI contrast agents
loaded into TSL, due to relaxivity changes induced by the agent
accumulation. Conception of correction methods is therefore
urgently needed. To overcome this problem, recently Shin et al.
proposed the use of perfluorocarbon nanoemulsions as 19F MR
contrast agent in sonosensitive systems, in order not to have
interferences with 1H based PRFS (Shin et al., 2017). However,
it seems quite challenging to obtain temporal information about
drug release using fluorinated compounds.
MRI Reporter Agents
Co-encapsulation of MRI agents into sonosensitive nanovesicles,
thus obtaining sonosensitive MRI agents, is of paramount
importance in order to monitor and assess in real-time the
drug release process. The most diffuse approach consists
in encapsulating small hydrophilic paramagnetic compounds,
based on Gd3+ or Mn2+ ions, in the aqueous core of
the nanovesicles. Upon the entrapment the MRI contrast is
“silenced,” due to reduced exchange rate of water molecules
across the liposomal membrane. When the agent is released,
the “quenching effect” is removed, allowing the detection of
a contrast enhancement. This contrast enhancement can be
estimated and used as reporter of the extent of drug delivery
(Ponce et al., 2007; de Smet et al., 2011; Tagami et al.,
2011; Rizzitelli et al., 2016). The first TSL encapsulating a
MR contrast agent was developed by Viglianti et al. who co-
loaded MnSO4 and doxorubicin in liposomes and detected a
change in relaxivity upon heat-triggered drug release (Viglianti
et al., 2004). De Smet et al. instead, entrapped into TSL
both the clinically approved contrast agent Gd-HPDO3A
and doxorubicin, demonstrating that: (i) the paramagnetic
compound did not affect doxorubicin loading and release,
(ii) the drug and the imaging agent were released simultaneously
upon heating and (iii) Gd3+ encapsulation within the aqueous
core quenched its relaxivity until release occurred (de Smet
et al., 2010). However, in both works release was obtained
with non-US mediated hyperthermia. Only one year later, the
system conceived by de Smet et al. was exploited for MR-
HIFU triggered drug release by Negussie et al. co-workers, who
demonstrated that upon HIFU stimulation the releases of the
drug and the imaging agent were comparable (Negussie et al.,
2011), thus paving the way to real-time drug release estimation
by MRI using the paramagnetic compound as doxorubicin
surrogate. Similar conclusions were drawn by Tagami et al.
who co-encapsulated Gd-DTPA and doxorubicin (Tagami et al.,
2011), and Rizzitelli et al. who demonstrated the feasibility of
stimulating with pulsed Low Intensity Non Focused Ultrasounds
(pLINFU) and tracking by MRI drug release from nanovesicles
doped with gadoteridol and doxorubicin (Rizzitelli et al., 2014).
In 2013, Han et al. developed a sonosensitive system loaded
with doxorubicin and endowed of a newly-synthesized Gd-
DOTA-DPPE lipid. These vesicles were intended to track drug
delivery by MRI, but were unable to report on drug release
as Gd3+ was incorporated in the vesicle membrane, thus
preventing the removal of the so-called “quenching effect”
(Han et al., 2013). Original approaches included the use of a
dysprosium chelate (Fowler et al., 2013) or Chemical Exchange
Saturation Transfer (CEST) contrast agents. Langereis and co-
workers loaded into TSL both a chemical shift agent (Tm-
HPDO3A, for 1H lipoCEST detection) and a highly fluorinated
compound (hexafluoro-phosphate, for 19F detection). When
the two agents were compartmentalized, liposomes could be
visualized solely by the CEST effect due to the influence of
the paramagnetic shift agent exerted over 19F-NMR resonance,
but once the release was triggered the lipoCEST contrast
enhancement vanished, while the 19F MRI signal appeared,
allowing release quantification (Langereis et al., 2009). Delli
Castelli et al. entrapped Eu-HPDO3A in ultrasound-sensitive
liposomes, resulting in a “quenched” paraCEST effect at 18
ppm, promptly restored following disruption of the liposomal
membrane (Delli Castelli et al., 2014). Finally, iron oxide
based contrast agents have been employed. For instance, it
has been shown that sonosensitive liposomes coated with
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TABLE 1 | Overview of preclinical studies performed with sonosensitive MRI agents.
Referencess LIPOSOMAL
FORMULATION
MRI PROBE DRUG DISEASE MODEL US SETUP
McDannold et al., 2004 DSPC:DSPG
(90:10 w/w)
Gd(DTPA-BMA) No Liver VX2 tumors
(rabbit)
HIFU
1.71 MHz
Negussie et al., 2011 DPPC:MSPC:DSPE-
PEG2000
(85.3:9.7:5.0 mol/mol)
Gd(HPDO3A) Doxorubicin VX2 tumor in thigh
muscle
(rabbit)
HIFU
1.2 MHz
de Smet et al., 2011 DPPC:HSPC:Chol:DPPE-
PEG2000
(50:25:15:3 mol/mol)
Gd(HPDO3A) Doxorubicin Subcutaneous 9L
gliosarcoma tumors
(rat)
HIFU
1.4 MHz
de Smet et al., 2013 DPPC:HSPC:Chol:
DPPE-PEG2000:DOTA-
DSPE
(50:25:15:3:1 mol/mol)
Gd(HPDO3A) Doxorubicin R1 rhabdomyosarcoma
tumors
(rat)
HIFU
1.4 MHz
Fowler et al., 2013 DSPE:DSPE-
PEG2000:Chol
(62:8:30 mol/mol)
Gd(DTPA-BMA)
Dy(DTPA-BMA)
No Subcutaneous prostatic
adenocarcinoma
(rat)
Pulsed HIFU
MHz
PRF 250Hz
Rizzitelli et al., 2016 DPPC:DSPC:Chol:DSPE-
PEG2000
(10:5:4:1 mol/mol)
Gd(HPDO3A) Doxorubicin Subcutaneous TSA
Breast Cancer
(mouse)
Pulsed LINFU
1 MHz/3 MHz
PRF 1Hz
Fan et al., 2016 DSPC:DSPG:DSPE-
PEG2000
(21:21:1 mol/mol)
Superparamagnetic
iron oxide (SPIO)
Doxorubicin C6 glioma
(rat)
FU
1 MHz
Hijnen et al., 2017 DPPC:HSPC:Chol:DPPE-
PEG2000
(50:25:15:3 mol/mol)
Gd(HPDO3A) Doxorubicin R1 rhabdomyosarcoma
tumors
(rat)
HIFU
1.44 MHz
HIFU, High Intensity Focused Ultrasounds; LINFU, Low Intensity Non Focused Ultrasounds; FU, Focused Ultrasounds.
hydroxyapatite and entrapping nanodots of SPIO in the
inorganic shell can release their content upon application of
ultrasounds, inducing changes in T∗2/T2 MRI contrast (Liu
and Huang, 2011). Lorenzato et al. developed temperature-
sensitive magnetoliposomes, encapsulating ultrasmall iron oxide
particles (USPIO), displaying significant differences in MRI
signal enhancement and relaxivities before and after HIFU
stimulation (Lorenzato et al., 2013). In the next paragraph the
most promising preclinical applications of sonosensitive MRI
agents will be reported.
PRECLINICAL STUDIES
A direct comparison of the performance of preclinical studies
involving sonosensitive MRI agents is not an easy task as they
vary not only in terms of liposomal formulation but also in the
type of ultrasounds employed to trigger the release (Table 1).
Basically, we can gather these works into three groups: (i) HIFU
exploited to induce hyperthermia to stimulate both the release of
the imaging agent and tissue ablation (no drugs encapsulated);
(ii) HIFU employed to trigger the release of both the imaging
and the therapeutic agent by hyperthermia; (iii) pLINFU used
to trigger the release of the drug and the imaging moiety by
mechanical effect. A representative example of the first group
is the work reported by McDannold et al. dealing with non-
stealth TSL loaded with Gd(DTPA-BMA). The liposomes were
injected in rabbits bearing VX2 liver tumors for MR monitoring
of thermal therapy carried out with HIFU, obtaining a good
match to traditional MR thermometry methods only in the liver
(McDannold et al., 2004). The aim was to provide a less motion-
sensitive technique to monitor temperature in real time.
Several works report on the design and testing of TSLs
loaded with doxorubicin and Gd3+ complexes, to track drug
release induced by US thermal effect (de Smet et al., 2011;
Negussie et al., 2011). In the study reported by De Smet
et al. TSL coencapsulating doxorubicin and Gd-HPDO3A were
administered to rats bearing subcutaneous 9L gliosarcoma
tumors. Local hyperthermia (42◦C) was applied for 30min
through HIFU and drug release was monitored with interleaved
T1 mapping of the tumor tissue, finding out a good correlation
between released doxorubicin and Gd3+ (de Smet et al., 2011).
In 2016 Lokerse et al. seeking for an optimized Dox-TSL
formulation, found that the prediction of liposomal efficiency
based merely on in vitro test is challenging (Lokerse et al.,
2016). One year later Hijnen et al. compared different MR-
HIFU treatment schemes, assessing that a combination protocol
of hyperthermia-induced drug delivery with TSL, followed by
ablation, resulted in a homogeneous drug distribution and in the
highest therapeutic effect (Hijnen et al., 2017).
The only preclinical study using pLINFU was published
by Rizzitelli et al. In this work, Gd-HPDO3A was loaded in
a Doxil R©-like preparation and administered to mice bearing
subcutaneous breast cancer. The most relevant aspect of this
study dealt with the achievement of complete tumor regression
following the injection of liposomes and the application of
pLINFU for drug release and cell membrane sonoporation.
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Worth of note is the fact that the used theranostic agent is made
of already clinically approved agents (Doxil R©, Gd-HPDO3A).
The authors outlined that this approach may offer the possibility
of predicting the therapeutic outcome in each patient, simply
looking at the MRI contrast enhancement 15min p.i. (Rizzitelli
et al., 2016). The latter aspect, also known as “dose painting,” is
of crucial importance in view of a more and more personalized
medicine.
CONCLUSION
Thisminireview underlines the novelty and the potentiality of the
topic, as most of the sonosensitive agents were developed in the
last few years. Chemistry plays a fundamental role in the selection
of the lipids composing the membrane, in order to boost drug
release under US stimuli, while stably trapping the content under
physio-pathological conditions in the absence of an external
stimulus. It is stressed how special attention has to be devoted
to the choice of the encapsulated MRI active compound, that
has to act as a quantitative reporter of drug release. Regrettably,
making critical comparison is rather difficult at present, due to
the lack of standardization of transducers and circuits, often
highly customized. However, even if a standardization of the
US setting protocol is still lacking, mathematical and practical
models are under development in order to predict the efficiency
of the various formulations, and the obtained in vivo results
appear very promising for a future clinical translation.
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